A gene-editing therapy for sickle cell disease, with a price tag of £1.65m, is to be offered to patients on the NHS in ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

What are the most important professional skills in your work and how do you hone them ... Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the nod for use by the ...

How does the drug work? The active drug is nirmatrelvir ... Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the nod for use by the NHS in England after an earlier ...

The reason TLC NAND is slower than MLC or SLC has to do with how data moves in and out ... as performing some of the same load-balancing work as a high-end storage array—SSDs don't deploy ...

In the vast number of fields where generative AI has been tested, law is perhaps its most glaring point of failure. Tools ...

Investors in the United States and abroad are girding themselves for a turbulent week amid a looming tariff war.

Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

Got work to do? Laptops built for business are thinner and more powerful than ever. Find your next mobile work companion: Check out our favorite business laptops, backed by our deep-dive reviews.

With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.

The Man I’m Seeing Has a Bizarre Postsex Habit. When Pressed About It, He Claims That It’s “Just How I Am.” ...